Caterpillar To Butterfly Sayings

GUNA SpA is launching a clinical research project

Guna S.p.A, azienda leader nel campo delle medicine complementari, ha dato il via da circa due anni ad un importante Progetto di Ricerca Clinica con l’intento di comprendere meglio l’azione farmacologica di alcune molecole biologiche preparate secondo metodiche innovative.

All’interno del Progetto di Ricerca Clinica di Guna S.p.A, vengono e verranno condotti studi riguardanti patologie importanti, ed i farmaci utilizzati in sperimentazione sono prodotti già in commercio, utilizzati da centinaia di medici, assolutamente sicuri e privi di effetti collaterali.

Uno degli studi in corso riguarda il trattamento biologico della Psoriasi volgare .

Lo studio dal titolo: “Citochine low-dose nel trattamento della psoriasi volgare” sarà effettuato con farmaci Adjustment of Physiological Medicine (PRM).

This is a multicenter pilot clinical study, randomized, double-blind crossover alternated according to a model of the total duration of six months, aims to determine the efficacy and safety of low-dose therapy with cytokines (IL-4, IL -10 and IL-11) in patients with mild psoriasis.

The criteria for admission to the study are:

• aged between 18 and 70 years
• less than PASI 10 ( Calculate here your )
• not take drugs antipsoriasis systemic (by mouth or injection) from at least 3 months
• antipsoriasis not use topical medications (creams and ointments) at least 15 days

Exclusion criteria from the study are:

• psoriasis guttate, palmoplantar, erythrodermic or pustular
• patients treated for other diseases with topical steroids and / or systemic anti-TNF drugs and immunoregulatory / immunosuppressants.

Patients who fall into these criteria and who wish to take part in clinical trials can search among participating physicians study closest to them and write to vincenzo.miranda @ guna.it for more information.

Gaybathhousealabama.com

DLQI (Dermatology Life Quality Index)